Literature DB >> 19664817

Screening for prostate cancer remains controversial.

David E Neal1, Jenny L Donovan, Richard M Martin, Freddie C Hamdy.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19664817     DOI： 10.1016/S0140-6736(09)61085-0

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  9 in total

1.  Cancer genetics-guided discovery of serum biomarker signatures for diagnosis and prognosis of prostate cancer.

Authors:  Igor Cima; Ralph Schiess; Peter Wild; Martin Kaelin; Peter Schüffler; Vinzenz Lange; Paola Picotti; Reto Ossola; Arnoud Templeton; Olga Schubert; Thomas Fuchs; Thomas Leippold; Stephen Wyler; Jens Zehetner; Wolfram Jochum; Joachim Buhmann; Thomas Cerny; Holger Moch; Silke Gillessen; Ruedi Aebersold; Wilhelm Krek
Journal:  Proc Natl Acad Sci U S A       Date:  2011-02-07       Impact factor: 11.205

Review 2.  Liquid Biopsy Based Circulating Biomarkers in Metastatic Prostate Cancer.

Authors:  Eshwari Dathathri; Khrystany T Isebia; Fikri Abali; Martijn P Lolkema; John W M Martens; Leon W M M Terstappen; Ruchi Bansal
Journal:  Front Oncol       Date:  2022-05-20       Impact factor: 5.738

3.  Socio-demographic inequalities in stage of cancer diagnosis: evidence from patients with female breast, lung, colon, rectal, prostate, renal, bladder, melanoma, ovarian and endometrial cancer.

Authors:  G Lyratzopoulos; G A Abel; C H Brown; B A Rous; S A Vernon; M Roland; D C Greenberg
Journal:  Ann Oncol       Date:  2012-11-12       Impact factor: 32.976

4.  Projecting prevalence by stage of care for prostate cancer and estimating future health service needs: protocol for a modelling study.

Authors:  Xue Q Yu; David P Smith; Mark S Clements; Manish I Patel; Bill McHugh; Dianne L O'Connell
Journal:  BMJ Open       Date:  2011-04-07       Impact factor: 2.692

5.  Risk profiles of prostate cancers identified from UK primary care using national referral guidelines.

Authors:  H Serag; S Banerjee; K Saeb-Parsy; S Irving; K Wright; S Stearn; A Doble; V J Gnanapragasam
Journal:  Br J Cancer       Date:  2012-01-12       Impact factor: 7.640

6.  Changing presentation of prostate cancer in a UK population--10 year trends in prostate cancer risk profiles in the East of England.

Authors:  D C Greenberg; K A Wright; A Lophathanon; K R Muir; V J Gnanapragasam
Journal:  Br J Cancer       Date:  2013-09-26       Impact factor: 7.640

Review 7.  Mass Spectrometry-Based Glycoproteomics and Prostate Cancer.

Authors:  Caterina Gabriele; Licia E Prestagiacomo; Giovanni Cuda; Marco Gaspari
Journal:  Int J Mol Sci       Date:  2021-05-14       Impact factor: 5.923

8.  Design and preliminary recruitment results of the Cluster randomised triAl of PSA testing for Prostate cancer (CAP).

Authors:  E L Turner; C Metcalfe; J L Donovan; S Noble; J A C Sterne; J A Lane; K N Avery; L Down; E Walsh; M Davis; Y Ben-Shlomo; S E Oliver; S Evans; P Brindle; N J Williams; L J Hughes; E M Hill; C Davies; S Y Ng; D E Neal; F C Hamdy; R M Martin
Journal:  Br J Cancer       Date:  2014-05-27       Impact factor: 7.640

9.  ENOX2-based early detection (ONCOblot) of asbestos-induced malignant mesothelioma 4-10 years in advance of clinical symptoms.

Authors:  D James Morré; Brandon Hostetler; David J Taggart; Dorothy M Morré; A W Musk; Bruce W S Robinson; Jenette Creaney
Journal:  Clin Proteomics       Date:  2016-01-22       Impact factor: 3.988
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.